LIDOCAINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Lidocaine Hydrochloride, and what generic alternatives are available?

Lidocaine Hydrochloride is a drug marketed by Abbott, Abraxis Pharm, Afaxys, Am Regent, Anthea Pharma, Aspiro, B Braun Medical, Bel Mar, Belmora Llc, Dell Labs, Elkins Sinn, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Huons, Intl Medication, Luitpold, Lyphomed, Mankind Pharma, Miles, Rising, Spectra Mdcl Devices, Watson Labs, West-ward Pharms Int, Wyeth Ayerst, Yiling, Cosette, Sentiss, Watson Labs Inc, Aurobindo Pharma Ltd, Hikma, Pharmobedient, Rubicon Research, Lannett Co Inc, Novitium Pharma, Paco, Pai Holdings Pharm, Sun Pharma Canada, The J Molner, Baxter Hlthcare, B Braun, Eastman Kodak, Empi, Extrovis, Actavis Mid Atlantic, and Chartwell Molecular. and is included in one hundred and eleven NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for LIDOCAINE HYDROCHLORIDE

US Patents:	0
Applicants:	48
NDAs:	111
Finished Product Suppliers / Packagers:	46
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2,146
Patent Applications:	4,314
DailyMed Link:	LIDOCAINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	PHASE4
Assiut University	NA
Sakarya University	NA

See all LIDOCAINE HYDROCHLORIDE clinical trials

Pharmacology for LIDOCAINE HYDROCHLORIDE

Drug Class	Amide Local Anesthetic Antiarrhythmic
Physiological Effect	Local Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for LIDOCAINE HYDROCHLORIDE

C01BB	Antiarrhythmics, class Ib
C01B	ANTIARRHYTHMICS, CLASS I AND III
C01	CARDIAC THERAPY
C	Cardiovascular system

C05AD	Local anesthetics
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D04AB	Anesthetics for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

R02AD	Anesthetics, local
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01HA	Local anesthetics
S01H	LOCAL ANESTHETICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02DA	Analgesics and anesthetics
S02D	OTHER OTOLOGICALS
S02	OTOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	LIDOCAINE HYDROCHLORIDE	lidocaine hydrochloride	INJECTABLE;INJECTION	083627-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	018461-002	Approved Prior to Jan 1, 1982	AP	RX	No	No
Hospira	LIDOCAINE HYDROCHLORIDE	lidocaine hydrochloride	INJECTABLE;INJECTION	088330-001	May 17, 1984		DISCN	No	No
Eugia Pharma	LIDOCAINE HYDROCHLORIDE	lidocaine hydrochloride	INJECTABLE;INJECTION	207182-002	Oct 30, 2017	AP	RX	No	No

Market Dynamics and Financial Trajectory for Lidocaine Hydrochloride

Last updated: February 19, 2026

What is the Current Market Size and Growth Rate?

Lidocaine Hydrochloride, a local anesthetic and antiarrhythmic agent, has a global market valued at approximately $500 million in 2022. The compound has experienced a compound annual growth rate (CAGR) of around 4.5% from 2018 to 2022. This growth is driven by expanding applications in procedural anesthesia, chronic pain management, and cardiac arrhythmia treatment.

Projected growth estimates suggest the market will reach $650 million by 2027, with key growth drivers including increased demand for minimally invasive procedures and rising prevalence of cardiovascular diseases.

Year	Market Value (USD million)	CAGR (%, 2018–2022)	Projected Market Value (USD million, 2027)
2018	400	-	-
2019	430	4.4	-
2020	460	4.4	-
2021	485	4.4	-
2022	500	4.5	-
2027	-	-	650

How Do Patent and Regulatory Environments Influence Market Dynamics?

Patent protections typically cover proprietary formulations, delivery systems, or new indications of lidocaine. Many patents filed between 2010 and 2015 expired or are close to expiration, leading to increased generic competition.

Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) have approved multiple formulations—including topical gels, patches, injectables, and IV solutions. The expiration of patent exclusivities in key markets has fostered a surge in generic suppliers, reducing prices and increasing accessibility.

What Are the Key Revenue Drivers?

1. Procedural Anesthesia: Lidocaine remains standard for local anesthesia in dental, dermatological, and surgical procedures. The rise in outpatient surgeries expands sales.

2. Chronic Pain Management: Topical formulations are increasingly utilized for neuropathic pain, boosting demand.

3. Cardiac Applications: Intravenous formulations are critical for stabilizing cardiac arrhythmias, with growth supported by cardiac disease prevalence.

4. Emerging Indications: Research into new uses—such as neuropathy and off-label applications—may expand markets.

How Do Competitive and Pricing Strategies Affect Revenue Streams?

A crowded market with generic competitors causes downward pressure on prices. Brand-name products retain premium pricing through formulations that claim superior efficacy or delivery mechanisms.

Market share concentrate among key companies, including:

• Mylan (now part of Viatris): Leading generic supplier.
• Madaus GmbH: Supplies branded intravenous solutions.
• Pfizer and GlaxoSmithKline: Hold patents for newer formulations.

Pricing varies significantly; branded injectables cost between USD 2 to USD 4 per vial, whereas generics average USD 1 to USD 2.

What Are the Supply Chain and Manufacturing Trends?

Manufacturing centers are predominantly located in North America, Europe, and India, where cost efficiencies enable competitive pricing. Supply chain disruptions, such as those experienced during the COVID-19 pandemic, briefly impacted availability but have since stabilized.

Recently, increased investment in API production capacity aims to meet rising global demand while also reducing reliance on single-source production sites.

What Is the Financial Outlook for Investors and R&D?

Historically, revenue growth has been steady with slight fluctuations due to patent expirations and market entry of generics. Expected revenue growth maintains a CAGR of approximately 4–5% over the next five years, assuming the continuation of current trends.

Research and development investments focus on:

• Formulation improvements (e.g., transdermal patches).
• Novel delivery systems to extend patent life.
• Investigating new therapeutic indications.

Large pharmaceutical companies allocate between 5% and 10% of regional revenues to R&D for these products.

Key Risk Factors

• Patent expirations accelerating generic competition.
• Regulatory challenges in new indication approvals.
• Price erosion due to intense competition.
• Supply chain disruptions affecting production costs and availability.

Summary

The Lidocaine Hydrochloride market faces gradual growth driven by procedural and cardiac applications, with increased generic competition exerting downward pressure on prices. Innovation in delivery systems and indications remains vital for sustaining revenue."

Key Takeaways

• Market size reached approximately $500 million in 2022, with a forecast of $650 million by 2027.
• Growth driven by procedural anesthesia, pain management, and cardiac applications.
• Patent expirations have introduced significant generic competition.
• Pricing varies, with branded products priced higher than generics.
• Supply chain stability and innovation in formulations are critical for future revenue.

FAQs

1. How does patent expiration impact Lidocaine Hydrochloride revenues?

Patent expirations allow generic manufacturers to enter the market, leading to price reductions and increased market share for generics, thereby lowering overall revenue for branded products.

2. What are emerging indications for Lidocaine Hydrochloride?

Research explores applications in neuropathic pain, off-label uses for cancer-related pain, and potential new delivery systems to improve patient compliance.

3. How has COVID-19 affected the supply and demand of lidocaine?

Disrupted supply chains initially caused shortages, but manufacturing capacity adjustments and diversification of sourcing have stabilized supplies, supporting steady demand.

4. Which regions represent the largest markets for lidocaine formulations?

North America holds the largest market share, followed by Europe and Asia-Pacific, driven by healthcare infrastructure and procedural volumes.

5. Are there any significant regulatory barriers affecting growth?

Regulatory hurdles primarily relate to approval of new indications and formulations. Existing approvals for common uses face minimal barriers unless attempting new therapeutic areas.

---

References

[1] Grand View Research. (2022). Lidocaine Hydrochloride Market Analysis.
[2] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products.
[3] European Medicines Agency (EMA). (2022). Approved Medicines Database.
[4] MarketWatch. (2022). Global Local Anesthetics Market Size.
[5] IQVIA. (2022). Global Pharmaceutical Price Trends and Market Shares.